Friday, October 16, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· October 6, 2026

Intellistake Acquisition Target NanoAi Assembles Navy SEAL-Led Team Having Experience Working with Microsoft Engineering, Science and Special Operations Logistics Ahead of Laboratory Testing at Dallas Op Center

View original at finance.yahoo.com

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • NanoAi is preparing for laboratory testing at the Op Center, now that the facility and team are in place.

    60% confidence

  • NanoAi's technology detects trace airborne threats at standoff distance, in real time, without physical contact, across wearable, drone, robotic, vehicle and fixed platforms for defense, law enforcement and critical infrastructure applications.

    60% confidence

  • The proposed acquisition of NanoAi remains subject to closing conditions.

    60% confidence

  • The NanoAi CTO has more than 35 years of experience and has led global engineering teams of more than 600 people.

    60% confidence

  • NanoAi has assembled a leadership team spanning special operations, global-scale engineering, science and defense logistics at its Dallas-Richardson Op Center, supporting the platform ahead of laboratory testing.

    60% confidence

  • Craig Micklich is a 12-year U.S. Navy SEAL veteran who would join the Intellistake Board upon closing of the acquisition.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com